Leila J. Williams
YOU?
Author Swipe
View article: WIP: Understanding the Experiences of Neurodivergent Learners in Engineering and Computing Majors
WIP: Understanding the Experiences of Neurodivergent Learners in Engineering and Computing Majors Open
This Work-in-Progress paper presents student-driven research into the experiences of neurodivergent learners in Engineering and Computing majors at an R1 institution in the southeastern United States. This work emerged from an undergraduat…
View article: Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens Open
Cell therapies such as tumor-infiltrating lymphocyte (TIL) therapy have shown promise in the treatment of patients with refractory solid tumors, with improvement in response rates and durability of responses nevertheless sought. To identif…
View article: Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens
Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens Open
Cell therapies such as Tumor Infiltrating Lymphocyte (TIL) therapy have shown promise in the treatment of patients with refractory solid tumors, with improvement in response rates and durability of responses nevertheless sought. To identif…
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric dimethyla…
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric dimethyla…
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Data from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Data from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Immune-checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of patients with melanoma. However, a majority of patients do not respond to these agents, and many responders ex…
View article: Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Autophagy activity regulated by the PI3K pathway plays a critical role in T cell-induced tumor apoptosis.
View article: Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Supplementary figures
View article: Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Supplementary figures
View article: Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Supplementary Methods
View article: Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
The effect of PI3Kbeta inhibitor on melanoma with PTEN loss.
View article: Data from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Data from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Immune-checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of patients with melanoma. However, a majority of patients do not respond to these agents, and many responders ex…
View article: Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies Open
Supplementary tables
View article: Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
T cell–mediated immunotherapies are promising cancer treatments. However, most patients still fail to respond to these therapies. The molecular determinants of immune resistance are poorly understood. We show that loss of PTEN in tumor cel…
View article: Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
List of genes which are differentially expressed in melanomas with PTEN loss.
View article: Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
List of genes which are differentially expressed in melanomas with PTEN loss.
View article: Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Supplementary Table S1. Patient characteristics of the single-agent anti-PD-1 cohort. Supplementary Table S2. List of primers used for gene expression analysis by real-time PCR. Supplementary Table S3. List of autophagy-related genes for o…
View article: Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Lymphocyte infiltration status and the expression level of MHC class I in tumors from patients with melanoma.
View article: Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Lymphocyte infiltration status and the expression level of MHC class I in tumors from patients with melanoma.
View article: Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Examples of increased VEGF expression in regions with loss of PTEN in melanoma patients with heterogeneous PTEN expression.